FDA approves talazoparib plus enzalutamide in prostate cancer with HRR gene mutations
FDA,
FDAApproved
Talazoparib (Talzenna) + enzalutamide
Adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations, detected by an FDA-authorized test
The trial behind it
TALAPRO-3
0.48
Radiographic progression-free survival hazard ratio
95% CI 0.36–0.65; p<0.0001
NR
Median radiographic progression-free survival
Not reached, vs 45.8 months with enzalutamide + placebo
Take-home
Talazoparib + enzalutamide now approved for mAPMN/S prostate cancer with HRR gene mutations. TALAPRO-3 delivered a clear rPFS benefit (HR 0.48).
-e6d6a8d836.png&w=3840&q=75)
